These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27124592)

  • 21. Phytohemagglutinin-activated human T cells induce lethal graft-versus-host disease in cyclophosphamide and anti-CD122 conditioned NOD/SCID mice.
    Hu Y; Gu Y; Cui Q; Fu H; Sheng L; Wu K; Liu L; Fu S; Yu X; Huang H
    Ann Hematol; 2012 Nov; 91(11):1803-12. PubMed ID: 22699803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
    Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
    Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells.
    Giannoni F; Hardee CL; Wherley J; Gschweng E; Senadheera S; Kaufman ML; Chan R; Bahner I; Gersuk V; Wang X; Gjertson D; Baltimore D; Witte ON; Economou JS; Ribas A; Kohn DB
    Mol Ther; 2013 May; 21(5):1044-54. PubMed ID: 23380815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional engraftment of human peripheral T and B cells and sustained production of autoantibodies in NOD/LtSzscid/IL-2Rγ(-/-) mice.
    Ishikawa Y; Usui T; Shiomi A; Shimizu M; Murakami K; Mimori T
    Eur J Immunol; 2014 Nov; 44(11):3453-63. PubMed ID: 25154613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Establishment of an xenogeneic acute graft-versus-host disease model in NOD/SCID mice by engraftment of G-CSF mobilized human mononuclear cells].
    Gao L; Wang JM; Xie LN; Zhou H; Qiu HY
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):87-91. PubMed ID: 18681307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation.
    Fujii H; Luo ZJ; Kim HJ; Newbigging S; Gassas A; Keating A; Egeler RM
    PLoS One; 2015; 10(7):e0133216. PubMed ID: 26176698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alloreactive T Cells Display a Distinct Chemokine Profile in Response to Conditioning in Xenogeneic GVHD Models.
    Kawasaki Y; Sato K; Nakano H; Hayakawa H; Izawa J; Takayama N; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Ito R; Hayakawa M; Ohmori T; Kanda Y
    Transplantation; 2019 Sep; 103(9):1834-1843. PubMed ID: 31461746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
    Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
    Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
    Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease.
    Bruck F; Belle L; Lechanteur C; de Leval L; Hannon M; Dubois S; Castermans E; Humblet-Baron S; Rahmouni S; Beguin Y; Briquet A; Baron F
    Cytotherapy; 2013 Mar; 15(3):267-79. PubMed ID: 23265769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy.
    Holler A; Zech M; Ghorashian S; Pike R; Hotblack A; Veliça P; Xue SA; Chakraverty R; Morris EC; Stauss HJ
    Haematologica; 2016 Apr; 101(4):482-90. PubMed ID: 26802053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.
    Alcantar-Orozco EM; Gornall H; Baldan V; Hawkins RE; Gilham DE
    Hum Gene Ther Methods; 2013 Oct; 24(5):310-20. PubMed ID: 23931270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rat stem cells developing in irradiated SCID mice fail to become tolerized and cause lethal graft-versus-host disease.
    Surh CD; Kosaka H; Sprent J
    Am J Pathol; 1997 Aug; 151(2):591-9. PubMed ID: 9250172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice.
    Bézie S; Charreau B; Vimond N; Lasselin J; Gérard N; Nerrière-Daguin V; Bellier-Waast F; Duteille F; Anegon I; Guillonneau C
    Blood Adv; 2019 Nov; 3(22):3522-3538. PubMed ID: 31730699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3-positive CD8+ T lymphocytes.
    Janikashvili N; Trad M; Gautheron A; Samson M; Lamarthée B; Bonnefoy F; Lemaire-Ewing S; Ciudad M; Rekhviashvili K; Seaphanh F; Gaugler B; Perruche S; Bateman A; Martin L; Audia S; Saas P; Larmonier N; Bonnotte B
    J Allergy Clin Immunol; 2015 Jun; 135(6):1614-24.e4. PubMed ID: 25630940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of type I diabetes transfer by glutamic acid decarboxylase 65 peptide 206-220-specific T cells.
    Kim SK; Tarbell KV; Sanna M; Vadeboncoeur M; Warganich T; Lee M; Davis M; McDevitt HO
    Proc Natl Acad Sci U S A; 2004 Sep; 101(39):14204-9. PubMed ID: 15381770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope.
    Dahan R; Gebe JA; Preisinger A; James EA; Tendler M; Nepom GT; Reiter Y
    J Autoimmun; 2013 Dec; 47():83-93. PubMed ID: 24090977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term human CD34+ stem cell-engrafted nonobese diabetic/SCID/IL-2R gamma(null) mice show impaired CD8+ T cell maintenance and a functional arrest of immature NK cells.
    André MC; Erbacher A; Gille C; Schmauke V; Goecke B; Hohberger A; Mang P; Wilhelm A; Mueller I; Herr W; Lang P; Handgretinger R; Hartwig UF
    J Immunol; 2010 Sep; 185(5):2710-20. PubMed ID: 20668220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inducible T-cell receptor expression in precursor T cells for leukemia control.
    Hoseini SS; Hapke M; Herbst J; Wedekind D; Baumann R; Heinz N; Schiedlmeier B; Vignali DA; van den Brink MR; Schambach A; Blazar BR; Sauer MG
    Leukemia; 2015 Jul; 29(7):1530-42. PubMed ID: 25652739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.